Thelansis

Recurrent or Metastatic Cervical Cancer Market Outlook Thelansis’s “Recurrent or Metastatic Cervical Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Recurrent or Metastatic Cervical Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have...

 Cervical cancer, a common malignancy in the female genital tract, is a significant concern due to its high mortality rate. It often goes undetected until advanced stages, with 13% of patients receiving a late diagnosis. Cervical cancer ranks as the second leading cause of cancer-related deaths among women aged 20 to 39. Metastatic cervical cancer, in particular, has a dismal prognosis, with previous studies showing a median survival of only 8-13 months. The 5-year survival rate for metastatic cervical cancer is a mere 16.5%, whereas localized cases have a much higher 91.5% survival rate. Recurrent cervical cancer typically manifests with vaginal symptoms such as discharge, bleeding, dyspareunia, or pain. During a pelvic exam, a mass or nodularity at the vaginal cuff, possibly extending to the pelvic side wall, may be detected. Vaginal disease can be tender to the touch and prone to bleeding easily. Single-site metastases are more common in metastatic and recurrent cases (68.7%) th...

  Cervical cancer is outside the pelvis, are classified as persistent/recurrent, metastatic cervical cancer patients. 13% of cervical cancer patients are diagnosed at advanced stages. The 5-year survival rate for metastatic cervical cancer is 16.5%, compared to 91.5% for localized cervical cancer. Cervical cancer is one of the most common malignancies in the female genital tract system. It is the second leading cause of cancer mortality in women aged 20 to 39 years. The prognosis of cervical cancer patients remains poor, especially in metastatic patients. Previous studies have shown that the median survival time of metastatic cervical cancer is only 8-13 months. Due to the poor prognosis, metastatic cervical cancer has become one of the main challenges in the world.   The metastatic and recurrent Cervical cancer Single-site metastasis accounted for 68.7%, and multi-organ metastases were relatively rare. Lung metastasis was the most common in single-site metastasis, account...